Results 1 to 10 of about 4,961 (248)

Idarucizumab more effectively reverses the anticoagulant effects of dabigatran acylglucuronide than dabigatran [PDF]

Scientific Reports
Dabigatran acylglucuronide, an active metabolite of dabigatran, exhibits higher plasma concentrations and distinct anticoagulant effects compared to dabigatran, suggesting that it may play a more significant role in overall anticoagulant activity than ...
Jong-Min Kim, Young Yoon Bang, Kyoung-Ah Kim, Jin-Woo Park, Ji-Young Park   +4 more
doaj   +4 more sources

Idarucizumab for Emergency Reversal of the Anticoagulant Effects of Dabigatran: Final Results of a Japanese Postmarketing Surveillance Study [PDF]

Cardiology and Therapy, 2023
Introduction Idarucizumab, a monoclonal antibody fragment that rapidly reverses the anticoagulant effects of dabigatran, was approved in Japan in September 2016, at which time an all-case, postmarketing surveillance (PMS) study was initiated to collect ...
Masahiro Yasaka, Hiroyuki Yokota, Michiyasu Suzuki, Hidesaku Asakura, Teiichi Yamane, Yukako Ogi, Takaaki Kimoto, Daisuke Nakayama   +7 more
doaj   +3 more sources

Retrospective Observational Study of Patients With Subdural Hematoma Treated With Idarucizumab [PDF]

Neurotrauma Reports, 2023
Use of anticoagulants is increasing with the aging of societies. The safe first-line drug is likely to be a direct oral anticoagulant (DOAC), but outcomes of treatment of traumatic brain injury (TBI) with anticoagulants are uncertain.
Eiichi Suehiro, Hideyuki Ishihara, Yohei Kogeichi, Tsunenori Ozawa, Koichi Haraguchi, Masaru Honda, Yumie Honda, Makoto Inaba, Ryusuke Kabeya, Naoaki Kanda, Kenta Koketsu, Nobukuni Murakami, Hidetoshi Nakamoto, Kotaro Oshio, Kuniyasu Saigusa, Takashi Shuto, Shuichi Sugiyama, Kenji Suzuyama, Tsuguaki Terashima, Mitsuharu Tsuura, Mitsutoshi Nakada, Hitoshi Kobata, Toshio Higashi, Nobuyuki Sakai, Michiyasu Suzuki   +24 more
doaj   +3 more sources

Practical use of idarucizumab

Кардиоваскулярная терапия и профилактика, 2023
The number of patients with indications for direct oral anticoagulants (DOACs) to prevent thrombotic events is steadily growing. However, in 1,1-2,2% of cases, ischemic strokes occur within DOAC therapy.
G. R. Ramazanov, E. A. Kovaleva, E. V. Klychnikova, S. S. Petrikov, N. A. Shamalov, I. S. Aliev, E. V. Shevchenko   +6 more
doaj   +3 more sources

Effectiveness and Safety of Dabigatran Reversal with Idarucizumab in the Taiwanese Population: A Comparison Based on Eligibility for Inclusion in Clinical Trials [PDF]

Medicina, 2023
Background and Objectives: The effectiveness and safety of idarucizumab for the reversal of the effects of dabigatran have been proven. However, there remains a paucity of literature comprehensively investigating outcomes in real-world patients.
Jhih-Wei Dai, Chien-Ho Wang, Chan-Lin Chu, Shu-Chen Liao   +3 more
doaj   +3 more sources

Idarucizumab in dabigatran-treated patients with acute stroke: a review and clinical update [PDF]

Frontiers in Neurology
Idarucizumab is an antibody fragment specific for the immediate reversal of dabigatran anticoagulation effects. The use of idarucizumab is approved for dabigatran-treated patients suffering from life-threatening or uncontrolled bleeding and those in need
Senta Frol, Senta Frol, Janja Pretnar Oblak, Janja Pretnar Oblak, Mišo Šabovič, Mišo Šabovič, George Ntaios, Pawel Kermer, Pawel Kermer   +8 more
doaj   +3 more sources

Outcome after intracranial hemorrhage under dabigatran and reversal with idarucizumab versus under vitamin-K-antagonists – the RIC-ICH study [PDF]

Frontiers in Neurology, 2023
BackgroundIntracranial hemorrhage (ICH) is a rare but serious side effect associated with the use of oral anticoagulants, such as dabigatran. The specific reversal agent for dabigatran, idarucizumab, is available for the management of individuals with ...
Nils Kuklik, Nils Kuklik, Anika Hüsing, Andreas Stang, Andreas Stang, Marcus Brinkmann, Marcus Brinkmann, Christoph C. Eschenfelder, Christian Weimar, Christian Weimar, Hans-Christoph Diener   +10 more
doaj   +3 more sources

Idarucizumab as Antidote to Intracerebral Hemorrhage under Treatment with Dabigatran [PDF]

Case Reports in Neurology, 2016
Background and Purpose: Non-vitamin K anticoagulants (NOAC) such as dabigatran have become important therapeutic options for the prevention of stroke. Until recently, there were only nonspecific agents to reverse their anticoagulant effects in a case of ...
Valentin Held, Philipp Eisele, Christoph C. Eschenfelder, Kristina Szabo   +3 more
doaj   +5 more sources

Reversal of dabigatran and apixaban-induced coagulopathy using idarucizumab, fibrinogen, and prothrombin complex concentrate: A case report [PDF]

Heliyon
This case report examines the combined use of fibrinogen concentrate, four-factor prothrombin complex concentrate (PCC), and idarucizumab, a specific antidote for dabigatran, to reverse the anticoagulant effects of dabigatran and apixaban-induced ...
Elia Morando, Lorenzo Losso, Massimo Carollo, Ilaria Costantini, Matilde Bacchion, Lucia Drezza, Giorgio Ricci   +6 more
doaj   +3 more sources

Costs and Healthcare Resource Utilization Associated with Idarucizumab or Andexanet Alfa Oral Anticoagulant Reversal in Patients Hospitalized with Life-Threatening Bleeds

Clinical and Applied Thrombosis/Hemostasis, 2022
Purpose: To assess costs and healthcare resource utilization (HCRU) associated with the use of idarucizumab for the reversal of dabigatran and andexanet alfa for the reversal of direct oral Factor Xa inhibitors.
Alex C. Spyropoulos MD, Bríain Ó Hartaigh PhD, Zhun Cao PhD, MA, Harjeet Caberwal PharmD, Craig Lipkin MS, Michaela Petrini PA-C, MHS, Cheng Wang MD, PhD   +6 more
doaj   +2 more sources